INTERLEUKIN-6 Receptor Binding Polypeptides
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2007/058587, filed Aug 17, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,618,966 | Methods for the Treatment of INTERLEUKIN-6 Receptor-Related Diseases and Disorders In force · High confidence UsedRemaining | Ablynx N.V. | In force | High confidence | ||
| US 9,617,341 | Methods for Blocking or Reducing Binding of INTERLEUKIN-6 to INTERLEUKIN-6 Receptor In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 9,611,326 | INTERLEUKIN-6 Receptor Binding Polypeptides In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 9,605,072 | Nucleic Acids That Encode INTERLEUKIN-6 Receptor Binding Polypeptides In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 8,629,244 | INTERLEUKIN-6 Receptor Binding Polypeptides In force · High confidence | Ablynx N.V. | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.